HYCOR Elects New Member to Board of Directors
GARDEN GROVE, Calif., July 19, 2012 /PRNewswire/ — HYCOR Biomedical, Inc., a leading manufacturer and marketer of in vitro diagnostic products for the global allergy, autoimmune and urinalysis markets, together with owner Linden, LLC, today announced the appointment of John Kershaw, President and CEO of Sysmex America, Inc., a global leader in the design and development of clinical diagnostic hematology, coagulation and urinalysis equipment and information management systems, to its Board of Directors as part of its global growth strategy.
“John Kershaw brings extensive international business experience from a market leading company and we look forward to his contributions as a member of the HYCOR team,” said Richard Novak, Chairman of HYCOR’s Board of Directors, and Operating Partner at Linden, LLC. “His insights and experience will be very valuable in helping to guide HYCOR in the years ahead as we continue to branch out internationally, particularly due to his time working in Europe and extensive knowledge of the Asia Pacific region.”
Kershaw joins HYCOR’s Board of Directors with more than 16 years of domestic and international experience and leadership with Sysmex Corporation where he held several senior management and executive positions, including Executive Vice President of Sysmex Europe and Chief Operating Officer, Managing Director, and a Board Member of Sysmex’s U.S. headquarters. In 2009, Kershaw was elevated to the position of President and CEO of Sysmex America, Inc. He is a fellow of the Association of Medical Technologists in the United Kingdom and serves as the company’s representative member of AdvaMed. As Director, Kershaw will support the HYCOR management team in a variety of capacities with a particular focus on international market expansion.
“The HYCOR team is pleased to have John Kershaw join our diverse and very talented group of advisors,” said Dick Aderman, CEO, HYCOR. “We are certain that he will have a great impact on key areas of our business, specifically providing his international experience during this important time of growth for the company.”
About HYCOR Biomedical, Inc.
Founded in 1981, HYCOR is a global manufacturer and marketer of in vitro diagnostics products. Since its founding, HYCOR has expanded its presence into urinalysis, allergy and autoimmune products used in clinical laboratories, hospitals and doctors’ offices worldwide. Among its products, HYCOR markets the HYTEC(TM), KOVA® and AUTOSTAT(TM) brands. The company is focused on delivering products that provide the highest value to clinicians through innovation, reliability and customer service. For more information, please visit www.hycorbiomedical.com.
About Linden, LLC
Linden is a Chicago-based private equity firm focused exclusively on leveraged buyouts in the healthcare and life science industries. Linden’s strategy is based upon three elements: i) healthcare and life science industry specialization, ii) integrated private equity and operating expertise, and iii) strategic relationships with large corporations. Linden’s portfolio includes BarrierSafe Solutions International, Behavioral Centers of America, Corpak MedSystems, Drayer Physical Therapy Institute, HYCOR Biomedical, and Ranir. For additional information, please visit www.lindenllc.com.
SOURCE HYCOR Biomedical, Inc.